These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Saving the mind faces high hurdles. Travis J Science; 2005 Jul; 309(5735):731. PubMed ID: 16051787 [No Abstract] [Full Text] [Related]
4. Alzheimer's disease. A firm base for drug development. De Strooper B; König G Nature; 1999 Dec; 402(6761):471-2. PubMed ID: 10591201 [No Abstract] [Full Text] [Related]
5. [Therapy of Alzheimer disease]. Kovács T Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816 [TBL] [Abstract][Full Text] [Related]
6. Switching from donepezil to galantamine: a double-blind study of two wash-out periods. Wilkinson DG; Howe I Int J Geriatr Psychiatry; 2005 May; 20(5):489-91. PubMed ID: 15852437 [No Abstract] [Full Text] [Related]
9. [Molecular pathology and therapeutics in Alzheimer's disease: amyloid beta-protein as a therapeutic target]. Ohyagi Y Fukuoka Igaku Zasshi; 2006 Sep; 97(9):261-8. PubMed ID: 17134029 [No Abstract] [Full Text] [Related]
10. The impact of journal advertisements on prescribers of cholinesterase inhibitors. Sauer J; Howard R Int J Geriatr Psychiatry; 2002 Oct; 17(10):976-8. PubMed ID: 12325061 [No Abstract] [Full Text] [Related]
11. The potential for BACE1 inhibitors in the treatment of Alzheimer's disease. Hussain I IDrugs; 2004 Jul; 7(7):653-8. PubMed ID: 15243867 [TBL] [Abstract][Full Text] [Related]
12. Adherence to cholinesterase inhibitors in patients with Alzheimer's disease. Blais L; Kettani FZ; Perreault S; Leroux JC; Forget A; Kergoat MJ J Am Geriatr Soc; 2009 Feb; 57(2):366-8. PubMed ID: 19207161 [No Abstract] [Full Text] [Related]
13. The potential of BACE inhibitors for Alzheimer's therapy. Potter H; Dressler D Nat Biotechnol; 2000 Feb; 18(2):125-6. PubMed ID: 10657070 [No Abstract] [Full Text] [Related]
14. [Secretases as targets for the treatment of Alzheimer's disease]. Luo HM; Gu F Sheng Li Ke Xue Jin Zhan; 2003 Apr; 34(2):189-92. PubMed ID: 12889164 [No Abstract] [Full Text] [Related]
15. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease. Waldemar G; Hyvärinen M; Josiassen MK; Kørner A; Lehto H; Wetterberg P Int J Geriatr Psychiatry; 2008 Sep; 23(9):979-81. PubMed ID: 18229874 [No Abstract] [Full Text] [Related]
16. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis. Harry RD; Zakzanis KK Hum Psychopharmacol; 2005 Apr; 20(3):183-7. PubMed ID: 15700322 [TBL] [Abstract][Full Text] [Related]
20. For debate: is the evidence for the efficacy of cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease convincing or not? Ames D; Kaduszkiewicz H; van den Bussche H; Zimmermann T; Birks J; Ashby D Int Psychogeriatr; 2008 Apr; 20(2):259-92. PubMed ID: 18252031 [No Abstract] [Full Text] [Related] [Next] [New Search]